drugset / Trial / NCT05944211
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized, controlled, open study to evaluate the efficacy and safety of Hetrombopag in the treatment of chemotherapy-induced thrombocytopenia(CIT) in patients with acute myeloid leukemia
Timeline
- Start
- 2023-07
- Primary completion
- 2026-07
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hetrombopag Olamine | Unknown | 7.5 mg | Oral |